Tracking positive cues from the equity market, Canara Robeco Asset Management Company and Rubicon Research Ltd made a strong debut on stock exchanges today.

Shares of Canara Robeco AMC opened at ₹280.25 on the NSE, marking a 5.4% premium over its issue price of ₹266. The market capitalisation stood at ₹5,588.67 crore.  

On the other hand, Rubicon Research delivered a stellar debut, listing at ₹620.10 per share, a 27.9% premium to its issue price of ₹485. The market capitalisation of the specialty pharmaceutical company rose to ₹10,216.17 crore.  

Meanwhile, the BSE benchmark Sensex was up 422 points at 83,028, and the NSE Nifty50 climbed 0.46% to 83,028.

Canara Robeco IPO subscribed 9.7x

The listing of Canara Robeco AMC was below street expectations as the stock was commanding a grey market premium (GMP) of ₹20 in the unlisted market, indicating listing to be around ₹286, up 7.52%.

The ₹1,326.13-crore Canara Robeco AMC IPO was subscribed 9.74 times, which was entirely an offer for sale of 4.99 crore shares. The issue, having a price band of ₹266 per share, opened for subscription between October 9-13.

Category-wise, the issue garnered 1.91 times subscription in the retail segment, 25.92 times in the qualified institutional buyers (QIB) category, and 6.45 times in the non-institutional investor (NII) category.

Rubicon Research IPO booked 109x

Rubicon Research listing was better than expectations as the stock was trading at ₹605 in the unlisted market, commanding a GMP of 24.74%.

The ₹1,377.50-crore IPO of Rubicon Research received an overwhelming response from investors, subscribing a massive 109.35 times overall, marking one of the strongest IPO showings of 2025. Segment-wise, the IPO was booked 37.40 times in retail portion, 137.09 times in QIB, and 102.70 times in NII.

The issue was a combination of a fresh issue of 1.03 crore shares worth ₹500 crore and an offer for sale of 1.81 crore shares worth ₹877.50 crore. The IPO opened on October 9, 2025, and closed on October 13, 2025, with the basis of allotment finalised on October 14.

(DISCLAIMER: The views and opinions expressed by investment experts on fortuneindia.com are either their own or of their organisations, but not necessarily that of fortuneindia.com and its editorial team. Readers are advised to consult certified experts before taking investment decisions.)